News
.
.
.
We would like to announce that after a long and productive run of 26 years MTRAC has served its purpose and has disbanded.
We would like to thank the many GPs, non-medical Prescribers, lay members, clinicians and other specialists who contributed to meetings, and supported the work.
.
This webpage and the guidance will remain available for the next six months, but will not actively be updated.
Guidance
June 2021: Fulltext updated guidance
- Sativex oromucosal spray for the treatment of spasticity in multiple sclerosis
- Sativex ESCA (using new RMOC shared care template)
.
January 2021: Fulltext guidance available
- Lidocaine medicated plaster for the treatment of Localised Neuropathic Pain (Unlicensed indication)
- Rivaroxaban for the secondary prevention of atherosclerotic events in adults with CAD or symptomatic PAD
.
October 2020: New product available: Implementation support
.
June 2020: new and fulltext guidance available
- NEW: Lidocaine medicated plaster for the treatment of Localised Neuropathic Pain (Unlicensed indication)
- FULLTEXT: SGLT2 inhibitors for the treatment of type 2 diabetes
MTRAC guidance on ingenol mebutate removed due to withdrawal of the marketting authorisation (more information)
.
January 2020: new guidance available
.
December 2019: updated guidance, ESCA (Essential Shared Care Agreement) and new RICaD (Rationale for Initiation, Continuation and Discontinuation) available:
Two supporting documents have been produced to address variations in local practice. The ESCA and RICaD are in Word(TM) format in order to allow local adaptation.
One local CCG has expressed serious concerns about the potential for hypocalcaemia if patients are not adequately followed up following a denosumab injection.
.
August 2019: fulltext guidance available
- Biologic and targeted-synthetic disease-modifying anti-rheumatic drugs (bDMARDs and tsDMARDs) for the treatment of refractory rheumatoid arthritis
- UPDATE: DPP-4 inhibitors for the treatment of type 2 diabetes.
.
July 2019: fulltext guidance available
.
May 2019: new and full-text guidance available
- NEW: Biologic and targeted-synthetic disease-modifying anti-rheumatic drugs (bDMARDs and tsDMARDs) for the treatment of refractory rheumatoid arthritis
- FULLTEXT: Dequalinium chloride for the treatment of bacterial vaginosis
- FULLTEXT: Cariprazine for the treatment of schizophrenia
.
March 2019: new guidance
.
February 2019: new guidance
- Dequalinium chloride for the treatment of bacterial vaginosis
- Cariprazine for the treatment of schizophrenia
.
January 2019: new fulltext guidance
.
December 2018: new fulltext versions available:
- Triple component inhalers for the treatment of chronic obstructive pulmonary disease (COPD)
.
October 2018: new guidance
.
September 2018: new guidance
- Triple component inhalers for the treatment of chronic obstructive pulmonary disease (COPD)
.
June 2018: fulltext now available
- Drug Class review of non vitamin-K antagonist oral anticoagulants (NOACs) for the treatment and secondary prevention of venous thromboembolism
- Eluxadoline for the treatment of irritable bowel syndrome with diarrhoea (update)
.
March 2018: new guidance
.
January 2018: new fulltext versions now available:
- Guanfacine for the treatment of attention deficit hyperactivity disorder (ADHD)
- Pitolisant for the treatment of narcolepsy
- Drug Class review of non vitamin-K antagonist oral anticoagulants (NOACs) for the prevention of stroke and systemic embolism in people with atrial fibrillation
.
September 2017: new guidance
- Guanfacine for the treatment of attention deficit hyperactivity disorder (ADHD)
- Pitolisant for the treatment of narcolepsy with or without cataplexy
.
July 2017: new guidance
.
June 2017: fulltext versions now available for:
- Opicapone as an adjunctive treatment in Parkinson's disease
- On the Horizon: Eluxadoline for the treatment of irritable bowel syndrome with diarrhoea
.
March 2017: MTRAC gains NICE Accreditation for the Commissioning Guidance Summaries. For full details please see the press release
March 2017: new and updated guidance
- Opicapone for the treatment of Parkinson's disease
- On the Horizon: Eluxadoline for the treatment of irritable bowel syndrome with diarrhoea
.
February 2017: new fulltext guidance
.
January 2017: new fulltext guidance
.
Latest Committee Meeting:
The MTRAC committee last met on Thursday 5th November to discuss its future remit and work plans.
.
Next Committee Meeting:
Thursday 21st January:
- Update of Sativex for the management of spasticity in multiple sclerosis
If you wish to request the review of a particular product please see the contact page for further details.
| Document |
|---|